A new clinical trial of heterologous – or ‘mix-and-match’ – combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.
A new clinical trial of heterologous – or ‘mix-and-match’ – combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.
In a study published in The Lancet Infectious Diseases, researchers investigated the effectiveness of the BBV152 vaccine among employees of the All India Institute of Medical Sciences.
COVID-19 Collection thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
The heterologous ChAd/BNT combination confers better protection against SARS-CoV-2 infection than the homologous BNT/BNT combination in a real-world observational study of healthcare workers.